Key result
Hypertension is a highly prevalent and major modifiable risk factor in cardiac transplant recipients that is associated with graft failure, vasculopathy, and premature death.
This review highlights the distinct pathophysiological mechanisms of post-transplant hypertension in cardiac recipients, emphasizing the role of denervation and immunosuppressive therapy in its management.
Vigilant BP control may warrant attention in cardiac transplant recipients; leaves open optimal targets and agents for prospective trials.
Hypertension is a common syndrome in adult and pediatric cardiac transplant recipients affecting the great majority of patients. Elevated blood pressure is a major potentially modifiable risk factor associated with cardiac graft failure, vasculopathy, arrhythmias, stroke, renal failure and premature death. This review discusses the magnitude of the problem, its distinct mechanisms, and certain issues of prevention and treatment of post-transplant hypertension.
No takes yet. Share an insight, caveat, or question.
Шевченко et al. (2017) conducted a review in Hypertension in cardiac transplant recipients. Hypertension is a highly prevalent and major modifiable risk factor in cardiac transplant recipients that is associated with graft failure, vasculopathy, and premature death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: